Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) for Infantile Colics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosis of IC according to Rome III criteria (2);~2. age ≥2 weeks to 4 months;~3. breast-fed or fomula-fed infants;~4. term delivery (≥37 weeks gestation at birth);~5. 5-minute Apgar score ≥7; and 6) birth weight ≥2500 g~Exclusion Criteria:~1. a major medical problem or acute illness;~2. family history of atopy;~3. history of antibiotic treatment before or during the study;~4. history of probiotic supplementation.

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
- Group B (Type: ACTIVE_COMPARATOR): All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
- Group C (Type: ACTIVE_COMPARATOR): All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution

Based on this trial design, predict the completion outcome and termination type (if applicable).